Cite
Cohan SL, Edwards K, Lucas L, et al. Reducing return of disease activity in patients with relapsing multiple sclerosis transitioned from natalizumab to teriflunomide: 12-month interim results of teriflunomide therapy. Mult Scler J Exp Transl Clin. 2019;5(1):2055217318824618doi: 10.1177/2055217318824618.
Cohan, S. L., Edwards, K., Lucas, L., Gervasi-Follmar, T., O'Connor, J., Siuta, J., Kamath, V., Garten, L., Chen, C., Thomas, J., Smoot, K., Kresa-Reahl, K., & Spinelli, K. J. (2019). Reducing return of disease activity in patients with relapsing multiple sclerosis transitioned from natalizumab to teriflunomide: 12-month interim results of teriflunomide therapy. Multiple sclerosis journal - experimental, translational and clinical, 5(1), 2055217318824618. https://doi.org/10.1177/2055217318824618
Cohan, Stanley L, et al. "Reducing return of disease activity in patients with relapsing multiple sclerosis transitioned from natalizumab to teriflunomide: 12-month interim results of teriflunomide therapy." Multiple sclerosis journal - experimental, translational and clinical vol. 5,1 (2019): 2055217318824618. doi: https://doi.org/10.1177/2055217318824618
Cohan SL, Edwards K, Lucas L, Gervasi-Follmar T, O'Connor J, Siuta J, Kamath V, Garten L, Chen C, Thomas J, Smoot K, Kresa-Reahl K, Spinelli KJ. Reducing return of disease activity in patients with relapsing multiple sclerosis transitioned from natalizumab to teriflunomide: 12-month interim results of teriflunomide therapy. Mult Scler J Exp Transl Clin. 2019 Jan 16;5(1):2055217318824618. doi: 10.1177/2055217318824618. eCollection 2019. PMID: 30729028; PMCID: PMC6350141.
Copy
Download .nbib